Genprex, Inc. announced the completion of the 0.09 mg/kg dose group in its Phase 1 clinical trial for Reqorsa Gene Therapy, with the Safety Review Committee approving escalation to the 0.12 mg/kg dose group, aiming to treat patients with extensive stage small cell lung cancer.